Abbie will be attending this year’s Redefining Early Stage Investments (RESI) held virtually on September 19th and 20th. RESI is committed to facilitating conversations that spark early-stage deals in across drugs, devices, diagnostics, and digital health that save lives and change the world through healthcare innovation. To advance the most successful deals, all major players, including both buyers and sellers, are saved a seat at the table. RESI attracts incubators, tech transfer offices, universities, hospitals, research labs and their constituents getting on the radar of investors and channel partners. Biotech, medtech, diagnostics, and digital health companies source global investors and strategic partners, create relationships, and pitch to secure funding from Seed to Series B*.
About RESI
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.